Company launches 19 products; Plans to expand the product line to 50 by 2026
- Oteria products are currently available on Amazon, Flipkart, and Oteria’s direct-to-consumer (D2C) platform www.oteria.com
- Focuses on generating awareness about holistic health for skin & creating skin equity
- Aims to build a gender-neutral skincare brand based on ‘circadian rhythm’ with 19 products
India, April 16, 2024: Rivpra Formulation, an integrated pharmaceutical company, today announced its entry into the D2C segment with the launch of its latest venture – a premium skincare brand, Oteria. Built on the concept of ‘circadian rhythm,’ Oteria is a gender-neutral brand providing holistic skincare solutions for both men and women. With a comprehensive approach to skin, hair, and body care, Oteria has launched 19 products and plans to launch 30 more products by 2026.
With more than 20 years in the market, Rivpra Formulation merges pharmaceutical expertise with its very own state-of-the-art facility to research, test, develop, and innovate products within Oteria’s portfolio, in line with the human body’s natural rhythm. Each ingredient undergoes testing in our own well-equipped labs so that we deliver high-quality efficacious products to consumers.
Commenting on the new launch, Vibhor Rastogi, Director, Rivpra Formulation Pvt. Ltd. shared, “Amidst the backdrop of the COVID-19 pandemic, there has been a notable surge in online shopping that reflects an increasing comfort level among consumers towards e-commerce platforms. This trend underscores a significant shift in consumer behaviour towards digital retail channels. Keeping that in mind, for Oteria, our primary focus is to connect directly with consumers by bringing our products to their doorsteps by partnering with the e-commerce and quick-commerce platforms whilst educating them about the importance of understanding one’s rhythm.
All of Oteria’s product line is manufactured at Rivpra Formulation’s independent manufacturing unit located in Sidcul, Haridwar which spans over 1,00,000 sq. ft through its subsidiary Medisch Lifesciences (distribution channel).
